Articles

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

Sibylle Loibl, Yeon Hee Park, Zhiming Shao, et al. N Engl J Med. 2026 Feb 26;394(9):845-857

A total of 1635 patients were randomly assigned (in a 1:1 ratio) to receive T-DXd (818 patients) or T-DM1 (817 patients). Invasive-disease events or deaths were reported in 51 patients (6.2%) in the T-DXd group and 102 patients (12.5%) in the T-DM1 group (hazard ratio, 0.47; P<0.001); 3-year invasive disease-fre... Read More

12 May, 2026

Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study

Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al. Ann Surg Oncol. 2026 Feb 25

We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study. After definitive surgery, participants received adjuvant pembrolizumab/placebo Q3W ... Read More

12 May, 2026

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N J Tutt, Judy E Garber, Bella Kaufman, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405

New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2germline pat... Read More

12 May, 2026

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

F Marmé, M Martin, M Untch, et al. ESMO Open. 2024 Jun;9(6):103466

The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compared to placebo. Here, we report results for premenopausal women. Overall, 616 of 1250 ra... Read More

12 May, 2026

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E Geyer Jr, Michael Untch, Chiun-Sheng Huang, et al. N Engl J Med. 2025 Jan 16;392(3):249-257

Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or dea... Read More

12 May, 2026

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Charles E Geyer Jr and Sibylle Loibl. Breast. 2025 Jun:81:104450

Reductions in HER2-protein IHC intensity and HER2-gene amplification in residual invasive breast cancer following neoadjuvant therapy for HER2-positive breast cancer have been described and are associated with worse outcomes. T-DM1 requires initial binding to HER2 for activity, so concerns have been raised regardin... Read More

12 May, 2026

Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial

Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al Eur J Cancer. 2025 Jun 18:223:115489

We assessed the association of BMI and weight changes with outcomes of patients with HER2-positive early BC included in the APHINITY trial. This is an exploratory analysis of APHINITY (NCT01358877), randomized trial testing adjuvant dual vs. single HER2 blockade plus chemotherapy in HER2-positive early BC. Of 4787 ... Read More

12 May, 2026

Trends in Mammography Use Among Women Aged 40 to 74 Years in the US, 2002-2022

Syed Mahfuz Al Hasan, Debbie L Bennett, Adetunji T Toriola. JAMA Netw Open. 2026 Mar 2;9(3):e263529

Objective: To analyze mammography use trends in US women aged 40 to 49 and 50 to 74 years from 2002 to 2022. Among 2,619,292 US women, mammography use showed a downward trend, with nonsignificant biennial changes of -0.54% for ages 40 to 49 years and -0.16% for ages 50 to 74 years from 2002 to 2022. Declines were s... Read More

12 May, 2026

Cost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada

Anna N Wilkinson, James G Mainprize, Martin J Yaffe, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2452821

Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards. Incremental cost-effectiveness ratios for deaths averted, life-years (LYs) gained, and incremental cost-utility ratios for quality-adjusted life-years (QALYs) gained were determ... Read More

12 May, 2026

Screening programmes and breast cancer mortality: an observational study of 194 countries

Syed Mahfuz Al Hasan, Debbie L Bennett, and Adetunji T Toriola. Bull World Health Organ.2025 Aug 1;103(8):470-483

We collected data on breast cancer screening programmes and breast cancer mortality from the World Health Organization's Global Health Observatory, the Global Burden of Diseases 2021 study and the Eurostat database. Between 2015 and 2021, 94 of 194 countries reported having national breast cancer screening program... Read More

12 May, 2026